This week on “The Top Line,” we’re diving into the topic of diversity in clinical trials, examining both the progress made and the ongoing work needed to ensure inclusivity.
In this episode, Fierce Biotech Senior Editor Annalee Armstrong engages in a conversation with Karen Correa, Ph.D., Head of Global Clinical Operations at Takeda and Executive Sponsor of Trial Diversity. Correa shares her insights into why it's imperative for pharmaceutical companies to adapt and prioritize diversity in their clinical trials, while also discussing the initiatives Takeda has undertaken in this area.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
The most anticipated drug launches of 2024
[Sponsored] Turning information into outcomes with MedThink Communications
[Sponsored] Talking technology and collaboration with Cytiva
Navigating the future of medical AI
Closing the $1 trillion women’s health gap
A closer look at the bounty of new drug approvals in 2023
The year in biotech
[Sponsored] Addressing the evolving needs of pharma for CDx development
A closer look at the Fierce 50
Turning down the toxicity of nature’s most powerful antifungal
Fiercest Women in Life Sciences, meet the Fierce 50
Exploring Alzheimer’s breakthroughs, Leqembi's potential and what comes next
A look at psychedelics and the next frontier of mental healthcare
Exploring the promise of earlier Alzheimer's treatment
A look at the FDA's Aduhelm approval and the potential for regulatory bias
Leqembi's full approval and the future of Alzheimer's treatment
Unraveling Alzheimer's disease treatments and a look ahead
[Sponsored] Modeling patient insights to make the most of clinical trials
Opportunities, challenges and uncharted territory in pharma marketing
Exploring AstraZeneca's environmental pledges
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Børsen Morgenbriefing
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast